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Available online 22 December 2015Niemann Pick type C (NP-C) is a rare neurodegenerative disorder caused by an impairment of intracellular lipid
transport. Due to the heterogeneous clinical phenotype and the lack of a reliable blood test, diagnosis and therapy
are often delayed for years. In the cell, accumulating cholesterol leads to increased formation of oxysterols that
can be used as a powerful screening parameter for NP-C. In a large scale study, we evaluated the oxysterol
cholestane-3β,5α,6β-triol (c-triol) as potential biomarker for a rapid diagnosis of NP-C. Using GC/MS, c-triol
has been analyzed in 1902 plasma samples of patients with the suspicion for NP-C. Diagnosis in patients with el-
evated oxysterols was conﬁrmed by genetic analysis. 71 new NP-C patients (69 NP-C1 and two NP-C2) and 12
Niemann Pick type A/B patients were identiﬁed. 24 new mutations in NPC1, one new mutation in NPC2 and
three new mutations in the SMPD1 gene were found. Cholestane-3β,5α,6β-triol was elevated in Niemann Pick
type C1, type C2, type A/B and in CESD disease. No other study has ever identiﬁed somany NP-C patients, proving
that c-triol is a rapid and reliable biomarker to detect patientswith NP-C disease and related cholesterol transport
disorders. It should replace the ﬁlipin test as the ﬁrst-line diagnostic assay.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:




Niemann Pick type C (NP-C) is a neurovisceral disease that is caused
by an impaired intracellular transport of cholesterol and glycolipids
based on mutations in the NPC1 or NPC2 gene (Carstea et al., 1997;
Naureckiene et al., 2000). NP-C is underdiagnosed and not readily iden-
tiﬁable due to a variable age of onset and a variety of age-dependent
symptoms. Whereas younger patients present primarily with visceral
symptoms such as hepatosplenomegaly followed by progressive intel-
lectual and neurological deterioration, adults often develop psychiatric
problems, including depression and psychosis (reviewed by Patterson
et al., 2012;Mengel et al., 2013). Due to the heterogeneous clinical phe-
notype, diagnosis is often delayed for many years or missed altogether.
Since a disease modifying therapy is available (Patterson et al., 2007)
and more are being developed, there is an urgent need for a reliable
and robust biomarker.stantriol, cholestane-3β,5α,6β-
age disease; EVS, exome variant
eiver-operating-characteristic.
ded by a grant from Actelion
ndmedizin, Albert-Schweitzer-
ardt).
. This is an open access article underInterruption of cholesterol transport leads to an increased non-
enzymatic oxidation of a very small fraction of the accumulated choles-
terol in NP-C cells. The oxidation products of cholesterol, called
oxysterols, can bemeasured by GC–MS or LC–MS/MS in human plasma.
It has been shown that 7-ketocholesterol (7-KC) and cholestane-
3β,5α,6β-triol (c-triol), are elevated in the plasma of NP-C1 and NP-
C2 patients (Porter et al., 2010; Boenzi et al., 2014; Reunert et al.,
2015; Jiang et al., 2011).
In a large scale investigator-initiated study, we evaluated c-triol as a
potential biomarker for the diagnosis of Niemann Pick type C disease.
Using GC–MS, 1902 plasma samples of patients with the suspicion of
NP-C disease, carriers of a heterozygous mutation in the NPC1 gene
and conﬁrmed NP-C patients were analyzed.
Our data demonstrate that analysis of plasma cholestane-3β,5α,6β-
triol fulﬁlls the need for a rapid and reliable biomarker for NP-C disease
and related cholesterol transport disorders, making diagnosis and early
therapy of these severe neurodegenerative disorders much easier.
2. Material and Methods
2.1. Patient Consents
Informed consent according to local laws was obtained from either
the patient or their legal guardians by the physician in charge.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2 ml EDTA-blood samples from patients suspected of having NP-C
disease were collected. Samples of ﬁve conﬁrmedNP-C1 patients, treat-
ed in our hospital, served as internal quality control. In order to include
heterozygote carriers of NP-Cmutations in the study, samples of parents
and siblings of known NP-C patients were collected as well. If arrival in
the laboratory within 48 h after drawing the blood was guaranteed, the
sample was sent at room temperature. Otherwise, the plasma was
separated from the cell pellet and both samples were sent on dry ice.
Process of sample handling after receipt of the c-triol result can be
seen in a ﬂow chart in the supplementary material (Fig. S1).
2.3. Chitotriosidase Activity
The chitotriosidase activity was measured as previously described
(Reunert et al., 2015; Hollak et al., 1994).
2.4. Mutation Analysis
In all samples with elevated plasma cholestane-3β,5α,6β-triol con-
centration, as well as in cases with strong clinical suspicion of NP-C
but normal oxysterols, conﬁrmatory molecular genetic analysis of the
NPC1 and NPC2 genes was performed. The coding region of NPC1
(NM_000271) andNPC2 (NM_006432) and ﬂanking intronic sequences
were ampliﬁed by PCR and analyzed by Sanger sequencing. Putative
mutations were conﬁrmed by sequencing independent PCR products.
In four cases, additional sequencing of the NPC1 or NPC2 transcript
was necessary to conﬁrm splicing defects. In positive samples that did
not contain more than one mutated allele for NPC1 or NPC2, a genetic
analysis of the SMPD1, GBA and/or LIPA genes was performed. Primer
sequences for NPC1, NPC2, and SMPD1, can be found in the supplement
(Supplementary Table S4), and primer sequences for GBA and LIPA are
available upon request. If available, parental samples were analyzed,
conﬁrming the segregation of the mutations.
2.5. GC–MS-analysis
100 μl plasma was used to quantify the cholestane-3β,5α,6β-triol
concentration. As internal standard, 10 ng of d7-cholestane-3β,5α,6β-
triol (Santa Cruz) was added. Measurement of cholestane-3β,5α,6β-
triol concentrations was done as described (Reunert et al., 2015). The
cut-off value was 50 ng/ml. In rare cases where only serum was avail-
able, serum instead of plasma was analyzed.
2.6. Role of the Funding Source
The funding organization did not play a role in design of the study,
interpretation of data, preparation and submission of the manuscript.
All authors had full access to all data in the study and the corresponding
author had ﬁnal responsibility for the decision to submit for publication.
3. Results
Within three years (2012–2014), cholestane-3β,5α,6β-triol was
measured in 1902 plasma samples of patients with suspected NP-C dis-
ease (Fig. 1). 1704 samples had a normal c-triol concentration.
3.1. Heterozygotes
Six out of 24 conﬁrmed carriers for a heterozygousmutation in NPC1
showed an increased c-triol concentration (s. Fig. 1). Three of these
samples underwent sequencing of the NPC1 and NPC2 genes, but only
the previously conﬁrmed heterozygous mutation was found.3.2. Previously Identiﬁed Patients
41 blood samples were drawn from ﬁve previously identiﬁed,
genetically conﬁrmedNP-C patients. Consecutive samples frompatients
were drawn upon routine follow-up visits in the hospital. All patients
were onmiglustat treatment. The c-triol concentration in these patients
was in the range of 60 to 300ng/ml, except for theﬁrst patient (s. Fig. 1).
This patient presented for the ﬁrst time at our hospital at the age of ten
weeks, with cholestatic jaundice and a profound hepatosplenomegaly.
The initial c-triol concentrations were massively increased up to
840 ng/ml. Although organomegaly did not improve with time, c-triol
concentrations decreased reaching the same range as the other con-
ﬁrmed NP-C1 patients.
3.3. Newly Identiﬁed NP-C Patients
80 samples of 72 different patients showed an increased c-triol con-
centration (s. Fig. 1). Subsequent genetic analysis in these 72 patients
revealed either a homozygous mutation or two compound heterozy-
gous mutations in NPC1 (n = 69) or NPC2 (n = 3) (s. Supplementary
Table S1). Three NP-C2 patients presented similar c-triol concentrations
as 69NP-C1 patients and could not be distinguished from the NP-C1 pa-
tients by c-triol analysis. One of these NP-C2 samples was a frozen
serum sample, preserved for several years. It belonged to a deceased
NP-C2 patient that had already been described by Griese et al. (2010).
NPC-2 details have been published (Reunert et al., 2015).
C-triol concentrations, chitotriosidase activities, ﬁlipin staining re-
sults (if available) and results of genetic analysis of all patients are sum-
marized in the Supplementary material (Table S1).
3.4. Speciﬁcity
33 patients have been false positive for NP-C. An elevated
amount of plasma c-triol was detected in all of these patients
(range 53–782 ng/ml), but in 30 patients no mutation in either NPC1
or NPC2 has been found; three patients were heterozygous for onemu-
tation in NPC1. In only two patients, a second sample was available
which also revealed a c-triol concentration N50 ng/ml.
In 12 patients, additional genetic analyses revealed compound het-
erozygosity or a homozygous mutation in the SMPD1 gene, identifying
them as Niemann Pick type A/B patients (including two of the pa-
tients with one heterozygous mutation in NPC1). The diagnosis of
the remaining patients is still unknown. In two patients with con-
ﬁrmed cholesterol ester storage disease (CESD) c-triol was also ele-
vated (121 ng/ml–181 ng/ml). Analysis of the false positives for
LIPAmutations did not reveal additional CESD patients. Further anal-
ysis of the GBA gene was done in two patients with a massively ele-
vated chitotriosidase, as typically seen in Gaucher's disease, but did
also not identify any mutations (see Supplement Table S3). In addi-
tion to the 33 false positive samples, there were 11 patients with
an elevated c-triol concentration, where the second sample revealed
normal values.
3.5. Sensitivity
In seven patients with normal c-triol concentrations, mutations
in NPC1 (n = 6) or NPC2 (n = 1) were detected, conﬁrming NPC dis-
ease. The chitotriosidase activity was elevated in three of these pa-
tients. Despite normal c-triol concentrations, a genetic analysis of
NPC1 or NPC2 was performed, as these patients presented typical
clinical symptoms, including ataxia, dysarthria, vertical supranuclear
gaze palsy, dysphagia and psychosis (see Supplementary Table S2).
In three of the seven patients, a second sample was available,
which also revealed a c-triol concentration below 50 ng/ml. Two of
the false negative NP-C patients showed a classical and three
Fig. 1. Cholestane-3β,5α,6β-triol-concentration in plasma of patients with suspicion of NP-C disease; yellow boxmarks the reference range, the dotted gray line indicates the cut-off value
of 50 ng/ml; in the previously known NP-C patients, all rhombuses in a vertical column belong to the same patient (only for the known NP-C patients).
172 J. Reunert et al. / EBioMedicine 4 (2016) 170–175patients showed a variant staining pattern in ﬁlipin testing (see Sup-
plementary Table S2).3.6. Sensitivity and Speciﬁcity
ROC analysis of 1811 samples was applied using MedCalc software.
With a cut-off of 50 ng/ml, a sensitivity of 91.8% and a speciﬁcity of
97.5% were determined.Fig. 2.Analysis of c-triol with respect to the age of patient/onset in the newly identiﬁed patients3.7. Correlation of C-triol with Age of Patient/Onset
When the c-triol concentration was analyzed with respect to
the age of the patients, only infantile patients with profound
organomegaly had higher values. In other age-groups, the concen-
tration of c-triol was age-independent (s. Fig. 2). Assuming that a
more severe burden of disease would lead to an earlier diagnosis,
higher oxysterol concentrations with younger age could have been
expected. However, this was not found.. Blue rhombuses represent NP-C1 patients; orange rhombuses represent NP-A/B patients.
Table 1
Summary of newly identiﬁed mutations in NPC1, NPC2 and SMPD1.
Exon/intron Nucleotide mutation






4 c.289T N A C97S Missense
4 c.302T N G F101C Missense
5 c.506A N T N169I Missense
5 c.527T N G L176R Missense
8 c.1028G N A G343E Missense
8 c.1042C N T R348X Nonsense
8 c.1171G N A E391K Missense
8 c.1182insT fs396X Frameshift
9 c.1448_c.1449delGT fs524X Frameshift
10 c.1654_1655insG fs557X Nonsense
IVS13 IVS13 + 2T N C Splicing
14 c.2198C N G P733R Missense
17 c.2597T N C M866T Missense
18 c.2683insG fs917X Frameshift
18 c.2759T N G V920G Missense
19 c.2849T N G V950G Missense
20 c.3010T N C S1004P Missense
IVS20 IVS20 + 5G N A Splicing
21 c.3134T N C L1045P Missense
22 c.3458insTC fs1159X Frameshift
23 c.3560C N G A1187G Missense
IVS24 IVS24 + 1G N Aa Splicing
IVS24 IVS24 + 3A N C Splicing
NPC2
IVS3 IVS3 + 6T N G ex3del/fs75X Splicing
SMPD1
1 c.271_272delinsCA C91H Missense
2 c.362T N C L121P Missense
3 c.1122C N A Y374X Nonsense
a IVS24 + 1G N C (Millat et al., 2001).
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In two patients, aged 8 and 9 years, c-triol was analyzed before and
duringmiglustat therapy. The eight year old patientmainly showed vis-
ceral (splenomegaly) and neurological symptoms (e.g. frequent falls).
The nine year old boy presented with visceral (splenomegaly) and
psychiatric symptoms (ADHD). During therapy, the progression of the
disease in both patients was largely stable. C-triol concentrations did
not decrease with miglustat treatment (s. Fig. 3).
3.9. Genetic Analyses
23 new mutations in NPC1were identiﬁed (s. Table 1), 13 missense
mutations (C97S, F101C, N169I, L176R, G343E, E391K, P733R, M866T,
V920G, V950G, S1004P, L1045P, A1187G), one nonsense mutation
(R348X), four splice-site mutations (IVS13 + 2T N C, IVS20 + 5G N A,
IVS24 + 1G N A, IVS24 + 3A N C) and ﬁve insertions or deletions
(c.1182insT, c.1448_c.1449delGT, c.1654_1655insG, c.2683insG,
c.3458insTC) leading to a frameshift and a premature stop codon. In
the NPC2 gene, two homozygous splice site mutations were identiﬁed,
IVS3+ 6T N Gwhich leads to the skipping of the complete exon 3 (con-
ﬁrmed by sequencing the transcript) and IVS4 + 1G N A, a known rare
variant (rs140130028). In SMPD1, three newmutations were identiﬁed
(C91H, L121P, Y374X) (s. Table 1). All newly described mutations have
been predicted to be disease causing by the online prediction program
“mutation taster” (Schwarz et al., 2014) and were not found in the
EVS (exome variant server) and HGMD (Human Gene Mutation Data-
base). An additional analysis by the prediction program provean, also
predicted a “deleterious” outcome for the missense mutations (Choi
et al., 2012).
3.10. Stability with Storage and Shipping
In order to examine the stability of c-triol at room temperature, plas-
ma samples from two conﬁrmed NP-C1 patients and from a healthy
control have been analyzed at different time points after storage at
room temperature. The concentration of plasma c-triol increased over
time, starting at 72 h after drawing the blood. The healthy control pre-
sented a c-triol concentration near the cut-off after nine days (s. Fig. 4).
4. Discussion
The lack of appropriate biomarkers for the diagnosis of Niemann
Pick type C leads to an underestimation of the incidence of this disease
which is thought to be 1:120,000–150,000 in Western Europeans
(Vanier and Millat, 2003). Indeed, Wassif et al. (2015) estimated the
combined incidence of NP-C1 and NP-C2 as 1:89,000. In the current
study, 71 new NP-C patients were diagnosed by oxysterol analysisFig. 3. Course of c-triol concentrations in two NP-C1 patients before and during miglustat thera
curve = eight year old patient presenting visceral and neurological symptoms.followed by genetic analysis in a time frame of three years (2012–
2014). Additionally, seven NP-C patients were identiﬁed by genetic
analysis combined with ﬁlipin staining or high clinical suspicion. 25%
of the heterozygote carriers (6/24) had c-triol levels above the cut-off
value. This is exactly the same frequency of positive carriers as reported
by Jiang et al. (2011) which shows the consistency of the assay across
different platforms and centers.
Due to the clinical heterogeneity, NP-C patients usually endure an
average diagnostic delay of 5–6 years (Sévin et al., 2007; Wraith and
Imrie, 2009; Stampfer et al., 2013). A reliable biomarker that is effective
at all ages and at all stages of the disease would be a beneﬁt for physi-
cians and patients. Bymeasuring c-triol in plasma,wewere able to iden-
tify NP-C patients from the age of 0.3–48.5 years, with variable
neurological involvement, showing that oxysterols, or at least c-triol,
are suitable as biomarker where age of onset and the degree ofpy; red curve = nine year old patient presenting visceral and psychiatric symptoms; blue
Fig. 4. Stability of cholestane-3β,5α,6β-triol at room temperature. Blue curve: healthy
control; red curve: conﬁrmed NP-C1 patient. After 72 h of incubation at room tempera-
ture, the concentration of c-triol increases in both samples.
174 J. Reunert et al. / EBioMedicine 4 (2016) 170–175neurological involvement are irrelevant. As amodifying therapy is avail-
able for Niemann Pick type C, the time to diagnosis is important
allowing earlier treatment. All NP-C1 patients identiﬁed prior to the
study were treated with miglustat. As expected, no effect of the
sphingolipid synthesis inhibitor miglustat on the c-triol concentration
was obvious which indicates that the measurement of c-triol cannot
be used to monitor miglustat treatment effects in NP-C patients.
Porter et al. (2010) stated that plasma oxysterol concentrations cor-
related with disease severity and age of onset. In our study, this was not
conﬁrmed in patients beyond infancy. In children with an infantile
onset, the c-triol concentration was higher than in juvenile and adult
onset of the disease. Twonewborn childrenwithmassive organomegaly
presented the highest c-triol concentrations measured in this study. In
one of them, the plasma c-triol decreased in the ﬁrst year of life. The
other child died after a few months.
The practicability of storage and shipping of the samples is an impor-
tant factor considering a reliable result. Sending samples on dry ice
would be the ﬁrst choice to maintain sample stability and avoid
autoxidation of the cholesterol, but is impractical and often impossible
for small hospitals. We show that after 72–96 h at room temperature,
the concentration of c-triol increased in the NP-C1 samples and in the
healthy control. Considering that the sample of the NPC1 patient
has already been pathological before incubation at RT, the elevation
from 255 to 293 ng/ml in ten days is negligible. However, the initial c-
triol concentration of the healthy control was 1 ng/ml and increased
to 28 ng/ml in nine days. Other healthy controls showed c-triol concen-
trations of 10–30 ng/ml and would have reached the cut-off shortly
after 72 h at room temperature. We recommend sending samples for
c-triol-analysis at room temperature when it can be guaranteed that
they arrive in the laboratory within 48 h. If the shipping time lasts
more than 48 h, a negative c-triol concentration could shortly reachthe cut-off. This would present a signiﬁcant risk of false positive sam-
ples, which includes further unnecessary analyses, e.g. genetic analyses
or a skin biopsy followed by ﬁlipin staining. Additionally, hemolysis
should be avoided as samples with hemolysis prior to centrifugation
also give false positive results (unpublished data;manuscript submitted
by Frank Kannenberg, Jerzy-Roch Nofer, Erhard Schulte, Janine Reunert,
Thorsten Marquardt, Manfred Fobker).
33 positive samples with only one or withoutmutations in theNPC1
or NPC2 gene were detected in this study. These false positive samples
did not exclusively arise by wrong shipping or storage conditions or
due to hemolysis. In 12 of these samples, mutations in the SMPD1
gene were found. These data show that c-triol is also increased in
Niemann Pick typeA/B patients. Lin et al. (2014), had shown that anoth-
er oxysterol, 7-ketocholesterol (7-KC) is also increased in Niemann Pick
type A/B patients. There are still several positive samples left where the
diagnosis is not known yet. We suggest that there might be other dis-
eases where a higher oxidation of the cholesterol occurs. Investigation
in two CESD patients (cholesterol ester storage disease) also revealed
higher concentrations of plasma c-triol. Most of the remaining positive
samples were screened for mutations in the LIPA gene, but nomutation
was found. In these cases we consider transcript analysis and/or whole
exome sequencing as next diagnostic steps. In the samples of 11 pa-
tients with elevated c-triol concentrations, a consecutive sample
showed normal results. In most of these cases the shipping duration of
the ﬁrst sample exceeded the recommended 48 h. In seven c-triol-
negative samples, a genetic analysis revealed disease causingmutations
in theNPC1 orNPC2 gene. The reasonwhy there are clinically and genet-
ically conﬁrmedNP-C patientswith a normal c-triol concentration is not
known yet and has to be further investigated. There might be more po-
tential false negative NP-C patients hidden in the cohort of samples that
were below the cut-off value, as a genetic analysis ofNPC1 andNPC2was
not usually performed in all samples. Jiang et al. (2011) also reported
2.7% of NP-C patients that were below the cut-off for their assay.
Several new mutations in the NPC1, NPC2 and SMPD1 genes were
found in this study. All thesemutations are predicted to be disease caus-
ing (online program “mutation taster” Schwarz et al., 2014) except for
the splice mutation IVS4 + 1G N A in NPC2, which is a known variant
(rs140130028). Only heterozygote patients with this mutation have
been described in the literature (Bauer et al., 2013), already presenting
symptoms of NPC disease. However, while the frequency of this variant
in the populationwas notmentioned in that paper, indeed itwas similar
to the frequency of the mutation in the NPC-patient group, and there-
fore heterozygosity for this mutation was most likely not causative for
the phenotype. Patient 73 carries the IVS4 + 1G N A mutation in a ho-
mozygous state and shows symptoms typical for NPC (see Table S2).
Further investigations on this patient and the splice mutation have
been initiated. The most common NPC1 mutations among western
Europeans, I1061T and P1007A, were found in 13/150 alleles (I1061T)
and 23/150 alleles (P1007A) respectively (I1061T: 3/13 South
America, 10/13 Europe; P1007A: 3/24 South America, 20/24 Europe).
In patients 84.1 and 84.2, one heterozygote mutation was found in
theNPC1 gene. After unsuccessful extensive sequencing, the second dis-
ease causingmutation could not be found and NP-C1 has been excluded
as suspected diagnosis. Due to the elevated c-triol concentration that
was also found in NP-A/B patients, the SMPD1 gene was sequenced
and two knownheterozygousmutations have been found. The presence
of one heterozygous mutation was puzzling and led to a diagnostic
delay.
However, in other cases deep intronic mutations that escape when
sequencing only exons and exon/intron-boundaries may lead to alter-
native splicing, instable mRNA, etc. effects that are only discovered by
complex further analyses e.g. of cDNA.
Other biomarkers are tested in parallel to the oxysterols, including
bile acids in urine and plasma parameters such as lysosphingolipids
or CCL18/PARC. In retrospective studies it has been shown that
lysosphingolipids and CCL18/PARC are also elevated in NP-C patients
175J. Reunert et al. / EBioMedicine 4 (2016) 170–175(Welford et al., 2014; Chang et al., 2010). There are no prospective
studies yet that show the clinical use of these promising parameters as
potential biomarkers for NP-C.
No other study has described the identiﬁcation of so many new
patients in such a short time frame. Oxysterol analysis is a rapid and
reliable assay for screening of patients suspected to have NP-C disease
and should replace the ﬁlipin test as the ﬁrst-line diagnostic assay.
Still, ﬁlipin staining should be performed in uncertain cases.
5. Conclusions
Our data demonstrate the clinical use of c-triol as potential biomark-
er for a rapid diagnosis of Niemann Pick type C disease. Measuring c-
triol in human plasma is cost-effective, is less invasive than other tradi-
tional tests andmight lead to a diagnosis at an early stage of the disease.
We show that c-triol is elevated in NP-C1, NP-C2, NP-A/B, and CESD
patients.
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